Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04531046
Title Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors The Lymphoma Academic Research Organisation
Indications

B-cell lymphoma

diffuse large B-cell lymphoma

follicular lymphoma

primary mediastinal B-cell lymphoma

Therapies

axicabtagene ciloleucel

Age Groups: adult | senior
Covered Countries FRA | BEL


No variant requirements are available.